Podcast: Alternative Drug Delivery Methods for Biologics: Where Are We At?
This podcast explores the challenges of and the progress made so far by the biopharma industry toward alternative drug delivering methods for biologic drugs.
Editor's note: this podcast was originally published on PharmTech.com.
Much work has been going into developing alternative routes of drug delivery for biologic therapeutics. The biopharmaceutical industry has been focusing on enhancing ease-of-use and patient compliance. Biologics today are mostly administered parenterally, which can be painful and undesirable for patients. Furthermore, parenteral formulations of biologics require a strict temperature-controlled environment.
Researchers have long been exploring means to formulate biologic-based molecules that can ensure their molecular stability and mitigate some of the stringent manufacturing requirements. In this episode of the Drug Solutions podcast, Feliza Mirasol, science editor of Pharmaceutical Technology®, Pharmaceutical Technology EuropeTM, and BioPharm International® explores the issues challenging biologic formulation and the progress made so far in moving toward alternative routes of biologic drug delivery with Nigel Theobald, CEO of N4 Pharma, a specialist pharmaceutical company developing novel delivery systems for oncology, gene therapy and vaccines.
About the Speaker
Nigel Theobald, CEO, N4 Pharma
Nigel Theobald is CEO of N4 Pharma, a specialist pharmaceutical company developing novel delivery systems for oncology, gene therapy and vaccines. Theobald has over 25 years’ experience in healthcare, in building businesses, strategy development and implementation, and in a strong network covering all aspects of pharmaceutical product development and commercialization. He was the head of healthcare brands at Boots Group plc in 2002 before leaving to set up a series of successful businesses, including Oxford Pharmascience Group plc, which he grew over five years into an AIM-quoted company with a market capitalization of £40 million (US$53 million) upon departure. Theobald formed N4 Pharma in 2014.
About the Drug Solutions Podcast
Pharmaceutical Technology presents the Drug Solutions podcast, where the editors will chat with industry experts from across the pharmaceutical and biopharmaceutical supply chain. Join us as experts share insights into your biggest questions—from the technologies, to strategies, to regulations related to the development and manufacture of drug products.
Listen to this podcast on SoundCloud, Spotify, Google Podcasts, or Apple Podcasts.
